GLP-1 and GIP also have extra pancreatic effects, which include a slowing of gastric emptying and central effects on the brain, leading to satiety and reduced appetite[1]
Coverage may be possible only when prescribed for FDA-approved non-weight-loss indications, subject to plan rules
The FDA now says there's no reason to compound medications that have a patent and that you can get supplied
Supporting your gut health isnt just about comfort
In general, the longer-acting GLP-1 agonists which are injected weekly, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), are associated with greater weight loss than the shorter-acting GLP-1 agonists such as liraglutide (Saxenda)
10.1111/dom.13761 Summary Keywords anti-inflammatory, atherosclerosis, coronary artery disease, glucagon-like peptide-1, mechanisms Citation Skrobucha A, Pindlowski P, Krajewska N, Grabowski M and Jonik S (2024) Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review
.jpg)
